HD-OPM Archive
Topics › Cancer

Daraxonrasib extends survival in treated metastatic pancreatic cancer (ASCO 2026)

Louis Nervegna · Jun 01, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
Cancer
AI summary & key facts

A quoted announcement of Phase 3 results presented at ASCO 2026, where the RAS inhibitor daraxonrasib helped patients with previously treated metastatic pancreatic cancer live longer than chemotherapy. It is a cancer topic, shared as notable medical news.

Quoted:

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: American Society of Clinical Oncology

#pancreaticcancerHD #daraxonrasibHD #cancerHD #rasHD #ascoHD #rasolute302HD

Research cited

← newer: Healthier thymus on CT linked to 63% lower cardiovascular deolder: RAS inhibitors are changing pancreatic cancer treatment, say →